X0609 4 2026-04-15 0000907654 Oruka Therapeutics, Inc. ORKA 0001756991 Goncalves Joana false C/O ORUKA THERAPEUTICS, INC. 855 OAK GROVE AVE., SUITE 100 MENLO PARK CA 94025 0 1 0 0 Chief Medical Officer 1 Common Stock 2026-04-15 4 M 0 3500 6.84 A 36877 D Common Stock 2026-04-15 4 M 0 3500 7.80 A 40377 D Common Stock 2026-04-15 4 S 0 4227 65.7291 D 36150 D Common Stock 2026-04-15 4 S 0 2273 66.5643 D 33877 D Common Stock 2026-04-15 4 S 0 500 67.3840 D 33377 D Employee Stock Option (right to buy) 6.84 2026-04-15 4 M 0 3500 0 D 2034-05-06 Common Stock 3500 211063 D Employee Warrant (right to buy) 7.80 2026-04-15 4 M 0 3500 0 D 2034-07-14 Common Stock 3500 182492 D These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.31 to $66.29, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.31 to $67.15, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.35 to $67.41, inclusive. The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. /s/ Paul Quinlan, as attorney-in-fact for Joana Goncalves 2026-04-15